Physician profile
Megan Patrick
NPI 1801419213
$925.02
in general payments reported to CMS, 2019-2025
18 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.00 · 2023: $233 · 2024: $214 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $153.07 | 2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $145.91 | 2023-2025 | |
| Novo Nordisk INC | $93.18 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $71.78 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $66.75 | 2023-2025 | Otezla, Repatha, Evenity |
| Dexcom, INC. | $56.60 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $44.47 | 2023-2024 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $40.06 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $35.47 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.97 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $26.84 | 2023-2024 | |
| Mylan Specialty L.P. | $26.06 | 2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $24.87 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $24.50 | 2025 | Injectafer |
| Astellas Pharma US INC | $22.50 | 2024 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $21.19 | 2023 | Qutenza |
| Abbott Laboratories | $19.94 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $16.86 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.